Table 2.
Distribution for age, gender, primary source, primary source country, presence of concomitant anti-diabetic agents among Individual Case Safety Reports (ICSRs) reporting at least one event of impaired glucose metabolism and having Pfizer–BioNTech, Moderna, Oxford–AstraZeneca, or Janssen Vaccine as suspected vaccine among those reported in Eudravigilance from 1 January 2021 to 11 December 2021.
| Variable | Level | Pfizer–BioNTech Vaccine (n = 2027) |
Moderna Vaccine (n = 586) |
Oxford–AstraZeneca Vaccine (n = 1163) |
Janssen Vaccine (n = 141) |
|---|---|---|---|---|---|
| Age | <18 years (%) | 53 (2.61) | 2 (0.34) | 8 (0.69) | 0 (0.00) |
| 18–64 years (%) | 1199 (59.15) | 332 (56.66) | 774 (66.55) | 102 (71.34) | |
| >65 years (%) | 636 (31.38) | 231 (39.42) | 278 (23.90) | 33 (23.40) | |
| Missing (%) | 139 (6.86) | 21 (3.58) | 103 (8.86) | 6 (4.26) | |
| Gender | F (%) | 1194 (58.91) | 331 (56.48) | 699 (60.10) | 68 (48.23) |
| M (%) | 804 (39.66) | 251 (42,83) | 437 (37.58) | 72 (51.06) | |
| Missing (%) | 29 (1.43) | 4 (0.68) | 27 (2.32) | 1 (0.71) | |
| Primary Source | Healthcare Professional (%) | 850 (41.93) | 411 (70.14) | 364 (31.30) | 81 (57.45) |
| Non-Healthcare Professional (%) | 1177 (58.07) | 175 (29.86) | 799 (68.70) | 60 (42.55) | |
| Primary Source Country for Regulatory Purposes | European Economic Area (%) | 1170 (57.72) | 165 (28.16) | 464 (39.90) | 36 (25.53) |
| Non-European Economic Area (%) | 857 (42.28) | 421 (71.84) | 699 (60.10) | 105 (74.47) | |
| Patients with concomitant anti-diabetic agents | Yes (%) | 507 (25.01) | 128 (21.84) | 424 (36.46) | 35 (24.82) |
| No (%) | 1520 (74.99) | 458 (78.16) | 739 (63.54) | 106 (75.18) |